VertigoDx logo

VertigoDx

Smartphone-based point-of-care vestibular testing with AI-guided nystagmus classification.

ShareLink copied

The record

Vertical
Medical Devices
Sub-segment
Vestibular diagnostics
Product type
Medical device
Stage
Private
Headquarters
Wilmington, DE and Miami, FL, USA
Region
North America
Founded
2025

What they do

SmartVertigo pairs a smartphone, light-occluding headset and software to capture horizontal, vertical and torsional nystagmus during positional testing. The prescription point-of-care system supports evaluation of vertigo, including benign paroxysmal positional vertigo. Developed with Florida Atlantic University, it received FDA 510(k) clearance under K260566 in July 2026, announced in September. Its leadership includes co-founder and CEO Paul Louis and co-founder Trevor Meyerowitz.

Leadership & founders

Leadership as of 14 November 2026.

History and progression

How VertigoDx got here, step by step.

  1. 29 September 2026

    FDA 510(k) clearance announced

    SmartVertigo Vestibular Assessment System cleared (K260566) as a prescription point-of-care platform.

Key products

SmartVertigo
Smartphone, light-occluding headset and software capturing horizontal, vertical and torsional nystagmus during positional testing, to evaluate vertigo including BPPV

Recent news

  1. 29 September 2026

    VertigoDx secures FDA 510(k) clearance for SmartVertigo

In The HealthTech Signal

Related companies

Is this your company? Get a Verified profile